Antibody-Drug Conjugates Enhance Outcomes in Advanced Triple-Negative Breast Cancer Patients Unsuitable for Immune Checkpoint Inhibitors
In a groundbreaking advancement in the treatment of aggressive breast cancers, researchers have unveiled promising results from the ASCENT-03 trial, ...
